ONC Q1 2026: Brukinza Drives 38% Growth, Pipeline Advances Signal Multi-Asset Inflection

2026-05-06 | By EarningsIQ Research

Brukinza’s global momentum and a robust innovation engine propelled ONC to raise 2026 revenue guidance by $100 million, underscoring commercial strength and late-stage pipeline acceleration. The hematology franchise continues to outperform, while solid tumor assets transition to pivotal stages, positioning ONC for a step-change in addressable opportunity. Investors should watch for pivotal trial readouts, regulatory catalysts, and the durability of recent margin gains as competitive dynamics intensify.

Summary

• Hematology Franchise Outperformance: Brukinza’s sustained leadership and new launches underpin global growth.
• Pipeline Maturity Accelerates: Multiple solid tumor and next-gen hematology assets advance to late-stage milestones.
• Margin Strength and Guidance Raise: Operating leverage and innovation productivity drive a higher full-year outlook.

Business Overview

ONC (B1 Medicines) is a global biopharmaceutical company focused on developing and commercializing therapies for hematologic malignancies and solid tumors. Its revenue model is anchored by proprietary oncology drugs—most notably Brukinza, a BTK inhibitor, and expanding next-generation assets like Sonro (BCL2 inhibitor) and BTK-CDAC (protein degrader). The business is structured around two major segments: hematology, which delivers the bulk of current revenue, and a growing solid tumor pipeline now entering pivotal stages.

Performance Analysis

ONC delivered a standout first quarter, with product revenue up 34% year-over-year, led by Brukinza’s 38% surge to $1.1 billion. The U.S. remains the largest market, posting 36% growth, while China and Europe contributed 17% and 64% growth, respectively. Rest of world markets more than doubled, reflecting new launches and expanded access. Gross margin improved to 89%, driven by mix and cost efficiencies, while operating expenses rose 16% as ONC invests in commercialization and R&D pipeline scale.

Notably, free cash flow improved by $173 million year-over-year, and operating income expanded sharply, reflecting both operational discipline and favorable product mix. The company’s decision to raise full-year revenue guidance by $100 million reflects confidence in continued demand, particularly in the U.S., and early signals of successful launches for new assets like Zanadatamab and Sonro.

• Brukinza’s Market Penetration: Global sales growth was broad-based, with volume and real-world data reinforcing its best-in-class positioning.
• Next-Gen Launches Gaining Traction: Sonro and BTK-CDAC are set to expand ONC’s hematology footprint and address new patient segments.
• Margin Expansion: Gross margin improvement to 89% reflects product mix and productivity initiatives, supporting higher operating leverage.

ONC’s financial discipline is evident in its ability to invest in pipeline expansion while expanding operating margins, setting the stage for sustained growth as late-stage assets mature.

Executive Commentary

Strategic Positioning

1. Hematology Franchise Leadership

Brukinza, BTK inhibitor, maintains clear leadership as the only agent with head-to-head superiority over ibrutinib, supported by robust six-year survival data. The franchise is being extended by next-generation launches (Sonro, BTK-CDAC) that target both fixed-duration and resistant disease segments, expanding ONC’s addressable market and clinical relevance.

2. Pipeline Scale and Focus

ONC’s innovation engine, powered by in-house platforms, is delivering a cadence of 8-10 new molecular entities per year. The pipeline is intentionally focused on select oncology and immunology indications, enabling proprietary combinations and higher internal ROI. Recent decisions to discontinue lower-priority programs (e.g., IRAC-4 in RA) reflect disciplined capital allocation.

3. Late-Stage Solid Tumor Inflection

Solid tumor assets, including the GPC341BB bispecific and CDK4 inhibitor, are advancing to pivotal trials in large markets like breast and liver cancer. The rapid progression from first-in-human dosing to registrational studies demonstrates ONC’s execution capability and positions the company for a step-change in solid tumor revenue contribution.

4. Global Expansion and Market Access

ONC is in early innings of European and rest-of-world launches, with substantial runway for Brukinza and upcoming combinations. Recent launches in Japan and Brazil, and ongoing reimbursement progress in Europe, are expected to sustain above-market growth.

5. Margin Expansion and Operating Leverage

Gross margin gains and disciplined OPEX growth are unlocking operating leverage, even as ONC invests heavily in late-stage trials and commercialization. Management is targeting sustainable margin improvement in line with pipeline maturation, supporting long-term earnings power.

Key Considerations

ONC’s Q1 2026 results reflect a company executing on both commercial and innovation fronts, with a clear strategy to dominate core hematology segments and expand into solid tumors. The strategic context is defined by:

Key Considerations:

• Commercial Execution Across Geographies: U.S. and Europe drive near-term growth, but rest-of-world markets are emerging as meaningful contributors.
• Pipeline Optionality: Proprietary combinations and new modalities (CDACs, bispecifics) increase the probability of late-stage success and market differentiation.
• Competitive Dynamics Intensifying: Biosimilar entrants and new BTK/BCL2 regimens are raising the efficacy and tolerability bar, requiring ONC to continually refresh evidence and differentiation.
• Regulatory and Guideline Milestones: Near-term catalysts include pivotal readouts, guideline inclusions, and potential accelerated approvals for key pipeline assets.

Risks

ONC faces meaningful risks from biosimilar competition, particularly for XGiva, and the potential for pricing pressure or slower-than-expected reimbursement in Europe and emerging markets. Pipeline execution risk remains, especially as multiple late-stage trials converge, and regulatory timelines or outcomes could introduce volatility. Competitive claims around rival BTK inhibitors also highlight the need for continued data leadership and commercial agility.

Forward Outlook

For Q2 2026, ONC guided to:

• Continued strong demand in core markets, with stable net pricing expected.
• Modest initial contributions from new launches (Zanadatamab, Sonro).

For full-year 2026, management raised guidance:

• Revenue range increased to $6.3–$6.5 billion.
• GAAP gross margin expected in the high 80% range.
• Operating income raised to $750–$850 million.

Management emphasized confidence in U.S. demand, ongoing global expansion, and a robust late-stage pipeline as key drivers for the updated outlook.

• Strong March and April demand trends in the U.S.
• Early innings in Europe and rest-of-world launches, with substantial growth runway.

Takeaways

ONC’s Q1 2026 results validate its dual-engine model: commercial execution in hematology and accelerating pipeline innovation. The company’s ability to expand its foundational franchise while scaling late-stage solid tumor assets sets up a multi-year growth trajectory.

• Commercial and Pipeline Synergy: Brukinza’s performance and next-gen launches create a durable revenue base, while proprietary pipeline combinations offer upside optionality.
• Disciplined Resource Allocation: Strategic pruning of lower-priority programs and focus on high-ROI assets enhances capital efficiency as pipeline complexity grows.
• Watch for Regulatory and Data Catalysts: Pivotal trial readouts, guideline inclusions, and accelerated approval submissions could drive valuation inflection points in coming quarters.

Conclusion

ONC enters the remainder of 2026 with clear commercial momentum, an expanding innovation pipeline, and rising operating leverage. The company’s ability to deliver on both near-term growth and long-term pipeline milestones positions it as a leader in oncology with asymmetric upside as late-stage assets mature.

Industry Read-Through

ONC’s results highlight the growing importance of multi-asset oncology franchises, where best-in-class data and proprietary combinations are key to maintaining leadership as competitive intensity rises. The company’s rapid pipeline progression and disciplined capital allocation set a benchmark for execution in the sector. For peers, the bar for differentiation continues to rise, especially in BTK/BCL2 and solid tumor markets, while biosimilar risk and pricing headwinds remain a sector-wide concern. The read-through for the industry is clear: scale, innovation velocity, and data-driven resource allocation are increasingly critical to sustaining growth and valuation in oncology.

ONC Healthcare Biotechnology Oncology Pipeline Hematology Solid Tumors Margin Expansion